News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story and see what’s trending.

No Picture
News

Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward

October 15, 2019 sandiegobiotech Comments Off on Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward

SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid … […]

No Picture
News

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

October 15, 2019 sandiegobiotech Comments Off on The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

Roche: The pharma giant delivered the blockbusters it had to have, here’s the second wave
AbbVie: A Phase III derailment costs AbbVie, but a big buyout and recent successes at the FDA help salve the wound
Merck: Can a single drug be too successful? An… […]

No Picture
News

Denovo Biopharma Receives FDA’s Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)

October 15, 2019 sandiegobiotech Comments Off on Denovo Biopharma Receives FDA’s Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)

SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced FDA’s approval to initiate Denovo’s Phase 2b clinical study of DB102 in patients with newly-diag… […]